Literature DB >> 8528849

Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.

C M Berard1, C D Mahoney.   

Abstract

A treatment algorithm and preprinted order form developed to reduce the cost of treating antineoplastic drug-induced nausea and vomiting are described. A team including pharmacists, oncologists, and oncology nurses developed a treatment algorithm to reduce the cost of antiemetic therapy for patients receiving antineoplastic therapy at a 719-bed academic medical center. The algorithm incorporated the following concepts: matching antiemetic therapy with the emetogenic potential of the antineoplastic regimen, reducing ondansetron dosages, increasing the ratio of oral to intravenous therapy, and treating delayed-onset nausea and vomiting without using serotonin-receptor antagonists. To help physicians learn and use the treatment algorithm, it was incorporated into an order form for both antineoplastic and antiemetic drugs. Separate order forms were created for pediatric and adult patients. A comparison of outcome data before and after implementation of the practice guidelines showed that the patient outcomes were at least as good after implementation as before. More than a year after the guidelines were implemented, more than 85% of antiemetic regimens prescribed for antineoplastic drug-induced nausea and vomiting were in compliance with the guidelines. A cost avoidance of nearly $205,000 was realized in the first year. Collaboration with oncologists at the start of the care plan was a key element in its success. An antiemetic treatment algorithm, integrated with a preprinted physician order form, was well accepted and has reduced expenses for antiemetic therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528849     DOI: 10.1093/ajhp/52.17.1879

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

Review 1.  From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care.

Authors:  Andrea Liekweg; Martina Westfeld; Ulrich Jaehde
Journal:  Support Care Cancer       Date:  2003-10-03       Impact factor: 3.603

Review 2.  Ondansetron: a review of its use as an antiemetic in children.

Authors:  C R Culy; N Bhana; G L Plosker
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Standard treatment of chemotherapy-induced emesis.

Authors:  D Warr
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

4.  Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.

Authors:  Toshinobu Hayashi; Hiroaki Ikesue; Taito Esaki; Mami Fukazawa; Motoaki Abe; Shinji Ohno; Tatsuru Tomizawa; Ryozo Oishi
Journal:  Support Care Cancer       Date:  2011-09-25       Impact factor: 3.603

Review 5.  Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  G L Plosker; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

6.  The cost of chemotherapy-induced nausea and vomiting in Italy.

Authors:  Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Stella Porrozzi; Mauro Iannopollo; Giancarla Soru; Giorgio Cruciani; Bruno Daniele; Maria Cristina Locatelli; James Pellissier; Robert Deuson
Journal:  Support Care Cancer       Date:  2006-06-21       Impact factor: 3.603

7.  Effects of Pharmacist-Led Clinical Pathway/Order Sets on Cancer Patients: A Systematic Review.

Authors:  Zhiyuan Tan; Zhiheng Yu; Ken Chen; Wei Liu; Rongsheng Zhao
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

Review 8.  Minimising treatment-associated risks in systemic cancer therapy.

Authors:  Ulrich Jaehde; Andrea Liekweg; Sven Simons; Martina Westfeld
Journal:  Pharm World Sci       Date:  2007-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.